|By PR Newswire||
|July 31, 2014 10:00 AM EDT||
SAN FRANCISCO, July 31, 2014 /PRNewswire/ -- Catylix, Inc. (Burbank, California) and Aspira Scientific (Milpitas, California) announced today the formation of a joint venture to develop and commercialize new fluorination products and related chemistry.
Developing improved biologically active molecules has benefited from the use of substituents that are chemically stable, resistant to metabolism, and combine lipophilicity with polarity to improve binding and bioavailability. Fluorinated functional groups are particularly well-suited to accomplish these objectives, often bringing improved efficacy and metabolic stability into compounds.
Catylix, Inc. and Aspira Scientific have created a joint venture to offer new fluorine-containing building blocks and reagents to customers in the pharmaceutical, agricultural, and specialty chemical industries. Dr. David Rozzell, CEO of Catylix, commented, "Through this joint venture with Aspira, Catylix will accelerate the development of its novel fluorination technologies and fluorine-substituted building blocks. Our goal is to expand our range of fluorination products and get these new compounds more quickly into the hands of chemists who need them."
Included in the product portfolio (www.aspirasci.com/fluorination) through this new joint venture will be Catylix's Trifluoromethylator® reagent for the synthesis of a wide range of CF3-containing compounds under mild reaction conditions. The broad compatibility with other functional groups allows "late-stage trifluoromethylation" during lead compound development and optimization for medicinal chemists. Dr. John Chan, CEO of Aspira stated, "The technical expertise of Catylix in fluorine chemistry together with Aspira's expertise in marketing, distribution, and production will allow rapid access of novel and unique fluorine-containing products, shortening screening and development time-lines for researchers. Aspira's access to cost-effective production facilities will ensure that these compounds will be available at economical cost structures on scale."
Dr. David Rozzell, CEO of Catylix, and Dr. John Chan, CEO of Aspira Scientific, will be available for discussions during the 2014 ACS Meeting and Exhibition in San Francisco on August 11 and 12, at Booth 1136.
About Aspira Scientific
Aspira Scientific is a science-centric enterprise dedicated to empowering scientists reach their aspirations in chemical R&D. We achieve this goal through reducing the cost of basic and applied research by offering research products with superior value in terms of price and quality. By leveraging a truly global innovation ecosystem, we also make available a broader set of next-generation enabling tools for chemical synthesis. For organizations with developmental programs, we provide custom production services via "Collaborate Locally. Commercialize Globally.™" model to afford exceptional value in terms of innovation, quality and IP assurance, and cost-efficiency. For more information on realizing your scientific aspirations now and tomorrow, please visit www.aspirasci.com.
About Catylix, Inc.
Catylix, Inc. is an early-stage company specializing in the development and commercialization of new fluorination chemistry and novel products for the incorporation of fluorine-containing functionality. For more information about Catylix, please visit http://www.catylix.com.
SOURCE Aspira Scientific
Developers want to create better apps faster. Static clouds are giving way to scalable systems, with dynamic resource allocation and application monitoring. You won't hear that chant from users on any picket line, but helping developers to create better apps faster is the mission of Lee Atchison, principal cloud architect and advocate at New Relic Inc., based in San Francisco. His singular job is to understand and drive the industry in the areas of cloud architecture, microservices, scalability ...
Apr. 27, 2017 03:00 PM EDT Reads: 3,563
Apr. 27, 2017 02:00 PM EDT Reads: 2,415
Apr. 27, 2017 01:45 PM EDT Reads: 1,285
Apr. 27, 2017 01:30 PM EDT Reads: 776
Apr. 27, 2017 01:15 PM EDT Reads: 1,444
Apr. 27, 2017 01:15 PM EDT Reads: 1,576
Apr. 27, 2017 01:15 PM EDT Reads: 4,946
Apr. 27, 2017 12:45 PM EDT Reads: 1,285
Apr. 27, 2017 12:45 PM EDT Reads: 2,698
Apr. 27, 2017 12:30 PM EDT Reads: 1,209
Apr. 27, 2017 12:30 PM EDT Reads: 1,039
Apr. 27, 2017 12:30 PM EDT Reads: 2,850
Apr. 27, 2017 12:15 PM EDT Reads: 3,136
Apr. 27, 2017 12:15 PM EDT Reads: 1,209
Apr. 27, 2017 12:00 PM EDT Reads: 1,312